FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
The latest resubmission addressed remaining CMC concerns, with the FDA confirming that the Phase III data was “sufficient”.
The latest resubmission addressed remaining CMC concerns, with the FDA confirming that the Phase III data was “sufficient”.
What's Your Reaction?
